KR20220128611A - 맥락적 희귀 코돈용 trem 조성물 및 관련 용도 - Google Patents

맥락적 희귀 코돈용 trem 조성물 및 관련 용도 Download PDF

Info

Publication number
KR20220128611A
KR20220128611A KR1020227018837A KR20227018837A KR20220128611A KR 20220128611 A KR20220128611 A KR 20220128611A KR 1020227018837 A KR1020227018837 A KR 1020227018837A KR 20227018837 A KR20227018837 A KR 20227018837A KR 20220128611 A KR20220128611 A KR 20220128611A
Authority
KR
South Korea
Prior art keywords
trem
contextually
fragment
seq
codon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227018837A
Other languages
English (en)
Korean (ko)
Inventor
크리스틴 엘리자베스 하이딘
데이비드 아서 베리
테오니 아나스타시아디스
누바 보고스 아페얀
Original Assignee
플래그쉽 파이어니어링, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 플래그쉽 파이어니어링, 인크. filed Critical 플래그쉽 파이어니어링, 인크.
Publication of KR20220128611A publication Critical patent/KR20220128611A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020227018837A 2019-11-04 2020-11-04 맥락적 희귀 코돈용 trem 조성물 및 관련 용도 Pending KR20220128611A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930361P 2019-11-04 2019-11-04
US62/930,361 2019-11-04
PCT/US2020/058948 WO2021092064A1 (en) 2019-11-04 2020-11-04 Trem compositions for con-rare codons and related uses

Publications (1)

Publication Number Publication Date
KR20220128611A true KR20220128611A (ko) 2022-09-21

Family

ID=73654885

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018837A Pending KR20220128611A (ko) 2019-11-04 2020-11-04 맥락적 희귀 코돈용 trem 조성물 및 관련 용도

Country Status (9)

Country Link
US (1) US20220364092A1 (enExample)
EP (1) EP4055163A1 (enExample)
JP (1) JP2023500116A (enExample)
KR (1) KR20220128611A (enExample)
CN (1) CN115003810A (enExample)
AU (1) AU2020379762A1 (enExample)
CA (1) CA3160097A1 (enExample)
MX (1) MX2022005362A (enExample)
WO (1) WO2021092064A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102930465B1 (ko) 2017-11-02 2026-02-25 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 ACE-tRNA를 이용한 유전 재할당을 통한 정지 코돈의 구조 방법
WO2021243301A2 (en) * 2020-05-29 2021-12-02 Flagship Pioneering Innovations Vi, Llc. Trem compositions and methods relating thereto
KR20230029685A (ko) * 2020-05-29 2023-03-03 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 Trem 조성물 및 이에 관련된 방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
WO2006105038A2 (en) * 2005-03-25 2006-10-05 The Uab Research Foundation Methods of altering gene expression and methods of treatment utilizing same
GB0600948D0 (en) * 2006-01-18 2006-02-22 Univ Dundee Prevention/Treatment Of Ichthyosis Vulgaris, Atopy And Other Disorders
US20120077224A1 (en) * 2009-06-05 2012-03-29 The Salk Institute For Biological Studies unnatural amino acid incorporation in eukaryotic cells
WO2012006551A2 (en) * 2010-07-08 2012-01-12 The Brigham And Women's Hospital, Inc. Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules
AU2013327059B2 (en) * 2012-10-02 2018-11-08 Vaxiion Therapeutics, Llc Immunomodulatory minicells and methods of use
CA2930665A1 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
MA39819A (fr) 2014-04-01 2017-02-08 Rubius Therapeutics Inc Méthodes et compositions d'immunomodulation
US20180135012A1 (en) 2015-05-13 2018-05-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
SI3402491T1 (sl) 2016-01-11 2022-05-31 Rubius Therapeutics, Inc. Sestavki in postopki v zvezi z multimodalnimi terapevtskimi celičnimi sistemi za indikacije raka
MX2019000205A (es) 2016-07-07 2019-09-23 Rubius Therapeutics Inc Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno.
US20180153989A1 (en) 2016-12-02 2018-06-07 Rubius Therapeutics, Inc. Compositions and methods related to cell systems for penetrating solid tumors
CN110520522A (zh) 2017-02-17 2019-11-29 鲁比厄斯治疗法股份有限公司 功能化红系细胞
CA3062426A1 (en) 2017-05-08 2018-11-15 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
WO2020069199A1 (en) * 2018-09-26 2020-04-02 Case Western Reserve University Methods and compositions for increasing protein expression and/or treating a haploinsufficiency disorder
CA3125567A1 (en) * 2019-01-18 2020-07-23 Flagship Pioneering, Inc. Trem compositions and uses thereof
WO2020243560A1 (en) * 2019-05-31 2020-12-03 Flagship Pioneering, Inc. Uses of trem compositions to modulate trna pools

Also Published As

Publication number Publication date
CN115003810A (zh) 2022-09-02
JP2023500116A (ja) 2023-01-04
WO2021092064A1 (en) 2021-05-14
AU2020379762A1 (en) 2022-05-26
MX2022005362A (es) 2022-09-23
US20220364092A1 (en) 2022-11-17
CA3160097A1 (en) 2021-05-14
EP4055163A1 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
US20220112489A1 (en) Trem compositions and uses thereof
EP3976782A1 (en) Uses of trem compositions to modulate trna pools
JP5291129B2 (ja) 細胞および／または組織および／または疾患フェーズ特異的な薬剤の製造方法
CN111405912A (zh) 用于基因组编辑的多核苷酸、组合物及方法
TW202102529A (zh) 用於多肽表現之多核苷酸、組合物及方法
EP2077326A1 (en) Novel nucleic acid
KR20220128611A (ko) 맥락적 희귀 코돈용 trem 조성물 및 관련 용도
JP2024506016A (ja) 免疫療法のためのｔ細胞免疫グロブリン及びムチンドメイン３（ｔｉｍ３）組成物及び方法
JP2025524456A (ja) Ｂ２ｍ発現のエピジェネティック制御のための組成物および方法
WO2022170194A2 (en) Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy
JP2023534304A (ja) Ｌｉｎｅ１の阻害剤及びその使用
JP7541100B2 (ja) ｓｉＲＮＡおよびその用途
Habib et al. Limited expression of non-integrating CpG-free plasmid is associated with increased nucleosome enrichment
EP4384191A1 (en) Compositions and methods for engineering stable tregs
EP4392060A1 (en) Programmed cell death protein 1 (pd1) compositions and methods for cell-based therapy
von Niessen Optimization of RNA cancer vaccines using 3’UTR sequences selected for stabilization of RNA Dissertation zur Erlangung des Grades Doktor der Naturwissenschaften
HK40032638A (en) Polynucleotides, compositions, and methods for genome editing
EA053115B1 (ru) Полинуклеотиды, композиции и способы редактирования генома

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000